153 related articles for article (PubMed ID: 30449658)
1. Immunotherapy toxicity predicted by circulating cytokines.
Gourd E
Lancet Oncol; 2018 Dec; 19(12):e676. PubMed ID: 30449658
[No Abstract] [Full Text] [Related]
2. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Ashida A; Sakaizawa K; Uhara H; Okuyama R
Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
[TBL] [Abstract][Full Text] [Related]
3. Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Fujimura T; Yamamoto Y; Hata H; Tanaka R; Yamaguchi K; Nonomura Y; Hirai I; Furudate S; Okuhira H; Imafuku K; Aoki M; Matsushita S
Br J Dermatol; 2018 Jul; 179(1):213-215. PubMed ID: 29405254
[No Abstract] [Full Text] [Related]
4. Severe rhabdomyolysis developing in an advanced melanoma patient treated by pembrolizumab followed by dabrafenib trametinib combined therapy.
Irimada M; Fujimura T; Kambayashi Y; Tsukada A; Takahashi T; Hashimoto A; Aiba S
J Dermatol; 2019 Jul; 46(7):e256-e258. PubMed ID: 30656733
[No Abstract] [Full Text] [Related]
5. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.
Lomax AJ; McGuire HM; McNeil C; Choi CJ; Hersey P; Karikios D; Shannon K; van Hal S; Carr U; Crotty A; Gupta SK; Hollingsworth J; Kim H; Fazekas de St Groth B; McGill N
Int J Rheum Dis; 2017 Sep; 20(9):1277-1285. PubMed ID: 28480561
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma.
Nakahara S; Fukushima S; Okada E; Morinaga J; Kubo Y; Tokuzumi A; Matsumoto S; Tsuruta-Kadohisa M; Kimura T; Kuriyama H; Miyashita A; Kajihara I; Jinnin M; Ihn H
J Dermatol Sci; 2020 Jan; 97(1):77-79. PubMed ID: 31843231
[No Abstract] [Full Text] [Related]
7. Discontinuation of melanoma combination immunotherapy.
Baker H
Lancet Oncol; 2017 Oct; 18(10):e565. PubMed ID: 28870612
[No Abstract] [Full Text] [Related]
8. Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma.
Chasseuil E; Saint-Jean M; Chasseuil H; Peuvrel L; Quéreux G; Nguyen JM; Gaultier A; Varey E; Khammari A; Dréno B
Acta Derm Venereol; 2018 Apr; 98(4):406-410. PubMed ID: 29327065
[TBL] [Abstract][Full Text] [Related]
9. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.
Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N
Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression as a potential predictive biomarker.
Fusi A; Festino L; Botti G; Masucci G; Melero I; Lorigan P; Ascierto PA
Lancet Oncol; 2015 Oct; 16(13):1285-7. PubMed ID: 26433815
[No Abstract] [Full Text] [Related]
11. Diet-dependent toxicity of ipilimumab in metastatic melanoma.
Majenka P; Hoffmann M; Rötzer I; Dimitrakopoulou-Strauss A; Koschny R; Longerich T; Enk A; Hassel JC
Eur J Cancer; 2019 Jan; 106():220-224. PubMed ID: 30528806
[No Abstract] [Full Text] [Related]
12. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
Kirkwood JM; Tarhini AA
J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
[No Abstract] [Full Text] [Related]
13. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
14. Cytokine release syndrome as an important differential diagnosis of severe skin toxicity with organ damage during switch from immunotherapy to targeted therapy in metastatic melanoma.
Dimitriou F; Mangana J; Micaletto S; Braun RP; Dummer R
Melanoma Res; 2019 Feb; 29(1):107-108. PubMed ID: 30557221
[No Abstract] [Full Text] [Related]
15. Ipilimumab prolongs survival in advanced melanoma.
Burki TK
Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
[No Abstract] [Full Text] [Related]
16. Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy.
Lim SY; Lee JH; Gide TN; Menzies AM; Guminski A; Carlino MS; Breen EJ; Yang JYH; Ghazanfar S; Kefford RF; Scolyer RA; Long GV; Rizos H
Clin Cancer Res; 2019 Mar; 25(5):1557-1563. PubMed ID: 30409824
[TBL] [Abstract][Full Text] [Related]
17. Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy.
Dimitriou F; Mangana J; Dummer R
Acta Derm Venereol; 2020 Jan; 100(1):adv00007. PubMed ID: 31626322
[No Abstract] [Full Text] [Related]
18. Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?
Kähler KC; Kosova K; Bohne AS; Schreiber S; Hauschild A
Eur J Cancer; 2020 Oct; 138():169-171. PubMed ID: 32890812
[No Abstract] [Full Text] [Related]
19. A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma.
Mei Y; Chen MM; Liang H; Ma L
Commun Biol; 2021 Mar; 4(1):383. PubMed ID: 33753855
[TBL] [Abstract][Full Text] [Related]
20. Utilization of immunotherapy among patients with stage 4 melanoma: An analysis of the National Cancer Database from 2012 to 2016.
Shah PV; Choi JN; Fiessinger L; Nardone B; Nguyen CV; Liszewski W
J Am Acad Dermatol; 2021 Mar; 84(3):811-814. PubMed ID: 32553633
[No Abstract] [Full Text] [Related]
[Next] [New Search]
